However, as antibody and antibody-fragment derived agents require administration of the radiolabeled agent several days before effective PSMA/tumor imaging can be performed, as this time is required for clearance of the tracer and optimal tumor/background signal. The gene discussed is FOLH1; the disease is neoplasm.